Alopecia News and Research

RSS

Alopecia is the lack or loss of hair from areas of the body where hair is usually found. Alopecia can be a side effect of some cancer treatments.

New treatment option could provide effective therapy for patients with dermatologic conditions

Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients' quality of life and overall health. An emerging treatment option, however, could provide effective therapy for patients with these conditions.

3 Mar 2017

Scientists attempt to slow down ageing using novel compound

A group of Russian and Swedish scientists just published a breakthrough paper, reporting results of a joint study by Lomonosov Moscow State University and Stockholm university. The article was published in the US journal Aging.

17 Feb 2017

Paxman's scalp cooling system shows to successfully reduce alopecia during chemotherapy in breast cancer patients

The results of Paxman’s first randomised US scalp cooling trial has been published in JAMA; a renowned peer-reviewed oncology medical journal published by the American Medical Association.

From Paxman 16 Feb 2017

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Pembrolizumab was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen.

22 Nov 2016

FDA approves new therapy for initial treatment of soft tissue sarcoma

The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues.

19 Oct 2016

JAK inhibitors show promise in restoring hair growth in patients with alopecia areata

Seventy-five percent of patients with moderate to severe alopecia areata--an autoimmune disease that causes patchy, and less frequently, total hair loss--had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center. By the end of their treatment, average hair regrowth was 92 percent.

5 Oct 2016

JAK inhibitors may be first effective treatment for people with alopecia areata

Seventy-five percent of patients with moderate to severe alopecia areata—an autoimmune disease that causes patchy, and less frequently, total hair loss—had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center. By the end of their treatment, average hair regrowth was 92 percent.

22 Sep 2016

BirchBioMed announces successful completion of Phase I trial for topical treatment to prevent scarring

BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial.

27 Aug 2016

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy.

19 Aug 2016

Scalp cooling provides safe, effective treatment in prevention of chemotherapy-induced alopecia

Scalp cooling is a safe, feasible and an effective treatment in the prevention of chemotherapy induced alopecia (CIA) according to a German study being presented at the American Society of Clinical Oncology Annual meeting (ASCO).

From Paxman 27 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Reducing hair loss during chemotherapy: an interview with Richard Paxman

The basic principle of chemotherapy is to damage the mitotic and metabolic processes in the cancer cells. The chemotherapy doesn't just target the cancer cells, it also targets the healthy cells, specifically ones that are rapidly dividing - our hair follicles are also rapidly dividing. We see damage to those hair cells, which then causes the hair to fall out.

From Paxman 19 Apr 2016

Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation.

21 Mar 2016

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).

7 Mar 2016

Paxman wins ‘Partnership with Academia Award’ for improving patient care with Huddersfield University

A UK healthcare manufacturer who specialises in scalp cooling has been awarded the prestigious ‘Partnership with Academia Award’ following an innovative two-year project with the University of Huddersfield.

From Paxman 2 Mar 2016

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.

23 Feb 2016

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

29 Jan 2016

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

28 Jan 2016

FDA clears for marketing first cooling cap to reduce chemotherapy-induced hair loss

Today, the U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy.

9 Dec 2015

Combining medications may increase HBsAg loss in HBV patients

Combining tenofovir disoproxil fumarate with pegylated interferon alfa-2a may improve the chances of hepatitis B surface antigen loss in patients with hepatitis B virus infection, suggests a randomised trial.

3 Dec 2015